Kabra Drugs Ltd.
| BSE: 524322 | Sector: Health care |
| NSE: N.A. | ISIN Code: INE323K01017 |
| BSE 00:00 | 16 Sep | 5.15 |
0 (0.00%) |
OPEN
5.67 |
HIGH
5.67 |
LOW
5.15 |
| NSE 05:30 | 01 Jan | Kabra Drugs Ltd |
| OPEN | 5.67 |
| PREVIOUS CLOSE | 5.15 |
| VOLUME | 216 |
| 52-Week high | 5.67 |
| 52-Week low | 2.67 |
| P/E | |
| Mkt Cap.(Rs cr) | 2 |
| Buy Price | 0.00 |
| Buy Qty | 0.00 |
| Sell Price | 0.00 |
| Sell Qty | 0.00 |
Kabra Drugs Ltd. (KABRADRUGS) - Net Sales
Market Cap
| COMPANY | LATEST(Rs) | CHG | CHG(%) | Net Sales (Rs crore) |
| Aurobindo Pharma | 722.10 | -11.50 | -1.57 | 15823.68 |
| Cipla | 967.00 | -1.05 | -0.11 | 13900.58 |
| Dr Reddy's Labs | 4792.80 | -3.20 | -0.07 | 13349.10 |
| Sun Pharma.Inds. | 769.70 | -0.05 | -0.01 | 12803.21 |
| Lupin | 926.20 | -14.20 | -1.51 | 11055.93 |
| Apollo Hospitals | 4732.45 | -361.90 | -7.10 | 9153.00 |
| Cadila Health. | 564.75 | -2.15 | -0.38 | 7790.40 |
| Glenmark Pharma. | 507.65 | -4.45 | -0.87 | 7567.93 |
| Alkem Lab | 4001.85 | 37.65 | 0.95 | 7219.68 |
| Divi's Lab. | 5101.80 | -111.05 | -2.13 | 6798.61 |
| Torrent Pharma. | 3100.25 | -1.95 | -0.06 | 6450.83 |
| Ipca Labs. | 2402.10 | -73.45 | -2.97 | 5114.11 |
| Alembic Pharma | 791.75 | -28.15 | -3.43 | 5051.44 |
| Laurus Labs | 609.80 | -12.15 | -1.95 | 4768.72 |
| Abbott India | 21189.15 | -399.30 | -1.85 | 4310.02 |
| Gland Pharma | 3847.40 | -62.70 | -1.60 | 3462.88 |
| Glaxosmi. Pharma | 1498.50 | -11.90 | -0.79 | 3193.74 |
| Granules India | 321.45 | 0.00 | 0.00 | 3134.98 |
| Sanofi India | 8079.05 | -119.70 | -1.46 | 2901.90 |
| Ajanta Pharma | 2173.00 | -10.80 | -0.49 | 2718.59 |
Quick Links for Kabra Drugs:
-
News
Announcements Brokerage Reports Business Earnings Sector -
Corporate Action
AGM Board Meetings Bonus Dividends EGM Rights Split -
INFORMATION
Bulk Deals Company History MF Holding Listing Info Locations Shareholding -
Financials
Financial Overview Balance Sheet Profit & Loss Cash Flow Ratios Quarterly Results Half Yearly Results Nine Monthly Results Yearly Results -
Annual Report
Auditors Report Chairman's Speech Company Management Directors' Report Finished Goods Raw Materials -
Peer Comparison
Competition Market Cap Price Price Performance Net Sales Net Profit Total Assets Historical Prices
